Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 612 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Accepts healthy volunteers

Sorting of Oral Sensations

NCT02390180
Conditions
Taste Qualities, Primary Tastes
Interventions
Tasting solutions
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Terminated Not applicable Interventional Accepts healthy volunteers

Glycemic Index of Commonly Consumed Sweeteners

NCT02931578
Conditions
Healthy
Interventions
Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Interventions
Oral glucose tolerance test (OGTT), Skin punch biopsy
Diagnostic Test · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Results available

Propranolol in Treating Hypoglycemia Unawareness

NCT03161964
Conditions
Type 1 Diabetes Mellitus
Interventions
Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
Drug
Lead sponsor
Anu Sharma
Other
Eligibility
21 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
Not listed Not applicable Interventional Accepts healthy volunteers

Early Screen and Treatment for Gestational Diabetes

NCT02377531
Conditions
Gestational Diabetes
Interventions
Early glucose screen group, Standard glucose screen group
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,020 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
Tampa, Florida
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Carnitine Palmitoyl Transferase Type 1A (CPT1A) Deficiency
Interventions
Medically supervised fasting
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Years to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
PreDiabetes, Adult Children
Interventions
Metformin, Digital Intervention
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 44 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

5HT2CR Balance in Brain Connectivity in Cocaine Dependence

NCT03921151
Conditions
Cocaine Dependence
Interventions
Mirtazapine 15 MG Oral Tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity

NCT01375803
Conditions
Insulin Resistance
Interventions
Novel dietary fiber, Placebo
Dietary Supplement · Other
Lead sponsor
Cargill
Industry
Eligibility
30 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisvile, Kentucky
Completed No phase listed Observational Accepts healthy volunteers

Muscle OXPHOS and Nutrient Homeostasis

NCT02920671
Conditions
Mitochondrial Diseases, Obesity
Interventions
Tracer-enhanced oral glucose tolerance test (OGTT*), Muscle MRI, Dual energy x-ray absorptiometry (DXA), Questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, long acting release, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Encino, California • La Jolla, California • San Diego, California + 21 more
Terminated Not applicable Interventional Accepts healthy volunteers

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

NCT04101045
Conditions
Type 1 Diabetes, De Novo Lipogenesis
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
13 Years to 22 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Conditions
Cardiorenal Syndrome
Interventions
Dapagliflozin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado